07:00 , Jul 7, 2003 |  BioCentury  |  Finance

Helping push open a window

Helping push open a window Historically, the public equity market has been busy before the IPO window opened, as shown by selected U.S. financing events between the bottoms of the last two biotech bear markets...
08:00 , Jan 22, 2002 |  BC Week In Review  |  Company News

Corixa, Beaufour Ipsen Group deal

CRXA granted Beaufour exclusive worldwide rights to its AnergiX.MG T cell inactivation technology to treat myasthenia gravis, an autoimmune neuromuscular disease. Beaufour is responsible for clinical and regulatory development. CRXA will receive an upfront license...
08:00 , Jan 15, 2002 |  BC Extra  |  Company News

Corixa licenses AnergiX.MG to Beaufour

CRXA granted Beaufour Ipsen (Paris, France) exclusive worldwide development and marketing rights to its AnergiX.MG T cell inactivation technology to treat myasthenia gravis, an autoimmune neuromuscular disease. CRXA will receive an upfront license fee and...
08:00 , Jan 8, 2001 |  BC Week In Review  |  Company News

Corixa, N.V. Organon deal

The companies amended a 1996 agreement between Organon and Anergen Inc. (Redwood City, Calif.), which CRXA acquired in 1999, to include the development of a recombinant form of Anergen's AnergiX.RA complex to treat rheumatoid arthritis...
08:00 , Jan 3, 2001 |  BC Extra  |  Company News

Corixa amends agreement with Organon

The companies amended an agreement between Organon (Oss, the Netherlands) and Anergen (Redwood City, Calif.), which CRXA acquired in 1999, to include the continued development of a recombinant form of Anergen's AnergiX.RA complex to treat...
07:00 , Oct 23, 2000 |  BioCentury  |  Strategy

CRXA does its part for M&A

If the generic advice of industry watchers to biotech is "merge thyself," Corixa Corp. is doing its bit. CRXA's deal to acquire Coulter Pharmaceutical Inc. is its fourth acquisition in the past two years. CRXA,...
07:00 , Apr 24, 2000 |  BC Week In Review  |  Company News

Corixa, N.V. Organon deal

CRXA received a $1 million milestone payment from partner Organon under a 1996 agreement between Organon and Anergen Inc. (Redwood City, Calif.), which CRXA acquired in 1999. The milestone was triggered by completion of a...
08:00 , Jan 4, 2000 |  BioCentury  |  Finance

1999 M&A activity

1999 M&A activity Company Acquired or merged company Value (M) Johnson & Johnson Centocor $4,900.0 Roche Genentech $4,200.0 Warner-Lambert Agouron $2,100.0 Shire Roberts $1,000.0 Celltech Medeva $912.0 Millennium LeukoSite $910.0 Pharmacia & Upjohn Sugen $728.5...
07:00 , Oct 4, 1999 |  BioCentury  |  Finance

3Q Market Review: Biobulls make their case

Overlooking the shaky conditions of the overall stock markets in the past two weeks, the reality is that the biotech sector has been on a tear. The BioCentury 100 was up 11 out of the...
07:00 , Jul 6, 1999 |  BioCentury  |  Finance

Money exists

Money exists In addition to Nomura, four other institutions plus some XEN managers exercised warrants yielding the company a total of £4.2 million. Nomura announced it would not reduce its shareholding further for at least...